Re-irradiation in clinical practice: results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform
Re-irradiation refers to a new course of radiotherapy either to a previously irradiated volume (irrespective of concerns of toxicity) or where the cumulative dose raises toxicity concerns [1]. This approach is now a viable treatment option for an increasing number of patients, as advances in systemic therapies have improved patient outcomes, and modern precision radiotherapy techniques have become widely available. Re-irradiation may be offered to patients with recurrent, metastatic, or new malignancies following initial radiotherapy in different anatomical regions [2 –6]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - October 6, 2023 Category: Radiology Authors: Jonas Willmann, Ane L Appelt, Panagiotis Balermpas, Brigitta G. Baumert, Dirk de Ruysscher, Morten Hoyer, Coen Hurkmans, Orit Kaidar-Person, Icro Meattini, Maximilian Niyazi, Philip Poortmans, Nick Reynaert, Stephanie Tandini-Lang, Yvette van der Linden, Tags: Original Article Source Type: research
Treatment options for Stage III-N2 Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Cohort Study
Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare and distinct subset of non-small cell lung cancer (NSCLC), accounting for a mere 0.9% of all lung malignancies. Its occurrence is intimately linked to Epstein-Barr virus (EBV) infection and is more prevalent in specific regions such as Guangdong Province, Hong Kong, Taiwan, and Singapore [1 –2]. In 2021, the classification of thoracic tumors by World Health Organization recognized PLELC as a variant of squamous cell carcinoma [3]. Nevertheless, PLELC exhibits noteworthy atypical characteristics within the NSCLC category. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - October 3, 2023 Category: Radiology Authors: Zan Hou, Ying Guo, Xiujiao Shen, Baiqiang Dong, Mingchun Li, Mingdian Wang, Qiong Li, Shining Li, Runzhe Chen, Ming chen Source Type: research
Risk of on-treatment lymphopenia is associated with treatment outcome and efficacy of consolidation immunotherapy in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy
The immune system plays a critical role in cancer development. The circulating lymphocyte count has been shown to be an important prognostic marker for survival outcomes in various types of cancer, including non-small cell lung cancer (NSCLC) [1,2]. A previous study reported that lung, heart, and whole body doses were associated with treatment-related lymphopenia during radiotherapy (RT), although the exact mechanism is unclear [2]. One possible theory may be that a large volume of low-dose radiation kills a vast number of circulating lymphocytes [2]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - September 30, 2023 Category: Radiology Authors: Gowoon Yang, Hong In Yoon, Joongyo Lee, Jihun Kim, Hojin Kim, Jaeho Cho, Chang Geol Lee, Jee Suk Chang, Yeona Cho, Jinsung Kim, Kyung Hwan Kim Tags: Original Article Source Type: research
Definitive radiotherapy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: a multicenter retrospective study (KROG 21-10)
In esophagus, due to the rich lymphatic channel extending from the submucosal layer to the thoracic duct, lymph can travel the entire length of the esophagus before draining into the lymph nodes, and makes the entire esophagus a potential risk area of lymphatic metastasis.[1,2] Thus, most of the cases present at an advanced stage, and the prognosis of such patients is dismal, with 5-year overall survival rate for all stages reported to be 14.3%.[3] (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - September 30, 2023 Category: Radiology Authors: Jun Yeong Song, Moon Sung Ho, Yang-Gun Suh, Jong-Hoon Kim, Dongryul Oh, Jae Myoung Noh, Jae-Uk Jeong, Ick Joon Cho, Min Kyu Kang, Jin Hee Kim, Young Suk Kim, Hun Jung Kim, Woo-Yoon Park, Byoung Hyuck Kim, Hak Jae Kim Source Type: research
Gating and intrafraction drift correction on a 1.5 T MR-Linac: Clinical dosimetric benefits for upper abdominal tumors
MR-guided stereotactic body radiotherapy (SBRT) has been established as a feasible therapy for unresectable tumors in the upper abdomen, with recent clinical outcomes demonstrating safe delivery of ablative doses with hypofractionated regimens, while maintaining low acute toxicity rates [1 –5]. The online adaptive workflow of MR-guided SBRT is characterized by the possibility to negate interfraction motion, but further margin reduction and dose escalation is now mainly limited by intrafraction motion. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - September 29, 2023 Category: Radiology Authors: Guus Grimbergen, Sara L. Hackett, Fasco van Ommen, Astrid L.H.M.W. van Lier, Pim T.S. Borman, Lieke T.C. Meijers, Eline N. de Groot-van Breugel, Johannes C.J. de Boer, Bas W. Raaymakers, Martijn P.W. Intven, Gert J. Meijer Tags: Short Communication Source Type: research
